The Risk Factors project has studied the very large HIV epidemic among injecting drug users (IDUs) in New York City from 1978 (using stored sera) to the present. HIV spread rapidly among lDUs in NYC reaching 50% prevalence by the time AIDS was discovered in 1981 and leading to over 50,000 cases of AIDS among lDUs in the city, almost 10% of all AIDS cases in the US. In the early 1990s, HIV prevention programs for IDUs were greatly expanded, and NYC has become one of the most important success stories in HIV prevention for IDUs. Since the early 1990s, HIV incidence among lDUs has declined from 5/100 person-years (py) to 1-2/ 100 py, and prevalence has declined from 50% to under 15% (a level not seen since 1978-79). There are still very important questions to be answered in this current prevention success story: (1) How far will declines in prevalence and incidence continue before a stable endemic situation develops? (2) There are currently substantial differences in prevalence among racial/ethnic groups--25% among Blacks vs. 5% among Whites, and 8% among Hispanics. Will prevention be successful for all racial/ethnic groups, or will the current differences persist indefinitely? (3) Now that injection-related HlV transmission has been greatly reduced, to what extent will continuing HIV infection be driven by sexual transmission? and (4) Will the success in reducing HIV also lead to success in reducing hepatitis C among lDUs in NYC? We will address these questions through: (a) continuation of our large-sample cross-sectional survey of risk behavior, social network factors, utilization of prevention services, HIV prevalence and HIV incidence (STAHRS testing); (b) mathematical modeling of HIV and STI transmission among lDUs and NIDUs; (c) exploratory testing of genetic differences of HIV strains among different racial ethnic groups in NYC; (d) large-sample HCV prevalence surveys, and (e) quantitative research syntheses of our data with other studies conducted on IDUs and NlDUs in NYC. The proposed research will provide information of great scientific interest and public health importance regarding the ability of prevention programs to control high HIV and HCV sero-prevalence epidemics, explaining racial ethnic differences in HIV infection, and examining sexual transmission of HIV among both lDUs and NIDUs.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
2R01DA003574-21
Application #
6746490
Study Section
Behavioral and Social Science Approaches to Preventing HIV/AIDS Study Section (BSPH)
Program Officer
Hartsock, Peter
Project Start
1994-09-10
Project End
2009-06-30
Budget Start
2004-07-01
Budget End
2005-06-30
Support Year
21
Fiscal Year
2004
Total Cost
$731,345
Indirect Cost
Name
Beth Israel Medical Center (New York)
Department
Type
DUNS #
075255364
City
New York
State
NY
Country
United States
Zip Code
10003
Des Jarlais, Don C; McKnight, Courtney; Feelemyer, Jonathan et al. (2018) Heterosexual male and female disparities in HIV infection at the end of an epidemic: HIV infection among persons who inject drugs in New York City, 2001-2005 and 2011-2015. Drug Alcohol Depend 185:391-397
Campbell, Aimee N C; Wolff, Margaret; Weaver, Laurel et al. (2018) ""It's Never Just About the HIV:"" HIV Primary Care Providers' Perception of Substance Use in the Era of ""Universal"" Antiretroviral Medication Treatment. AIDS Behav 22:1006-1017
Des Jarlais, D C; Cooper, H L F; Arasteh, K et al. (2018) Potential geographic ""hotspots"" for drug-injection related transmission of HIV and HCV and for initiation into injecting drug use in New York City, 2011-2015, with implications for the current opioid epidemic in the US. PLoS One 13:e0194799
Jõgeda, Ene-Ly; Avi, Radko; Pauskar, Merit et al. (2018) Association of IFN?4 rs12979860 polymorphism with the acquisition of HCV and HIV infections among people who inject drugs. J Med Virol 90:1779-1783
Des Jarlais, Don C; Arasteh, K; Feelemyer, J et al. (2018) Hepatitis C virus prevalence and estimated incidence among new injectors during the opioid epidemic in New York City, 2000-2017: Protective effects of non-injecting drug use. Drug Alcohol Depend 192:74-79
Elliott, Jennifer C; Hasin, Deborah S; Des Jarlais, Don C (2017) Perceived health and alcohol use in individuals with HIV and Hepatitis C who use drugs. Addict Behav 72:21-26
Jõgeda, Ene-Ly; Huik, Kristi; Pauskar, Merit et al. (2017) Prevalence and genotypes of GBV-C and its associations with HIV infection among persons who inject drugs in Eastern Europe. J Med Virol 89:632-638
Des Jarlais, Don C (2017) Harm reduction in the USA: the research perspective and an archive to David Purchase. Harm Reduct J 14:51
Des Jarlais, Don C; Arasteh, Kamyar; Feelemyer, Jonathan et al. (2017) Decline in Herpes Simplex Virus Type 2 Among Non-Injecting Heroin and Cocaine Users in New York City, 2005 to 2014: Prospects for Avoiding a Resurgence of Human Immunodeficiency Virus. Sex Transm Dis 44:85-90
Des Jarlais, Don C; Arasteh, Kamyar; McKnight, Courtney et al. (2017) What happened to the HIV epidemic among non-injecting drug users in New York City? Addiction 112:290-298

Showing the most recent 10 out of 139 publications